Viatris Inc (VTRS) Risk Factors

Recent key developments

Concrete developments — dated events, named agreements and instruments, legal proceedings — that Viatris Inc surfaced in its latest filing.

• EWSR (Enterprise-Wide Strategic Review) initiated in 2025, involving headcount reductions of up to approximately 10% and an anticipated facility closure.2025
• Acquisition of development programs for selatogrel and cenerimod, currently in Phase 3 development.
• Acquisition of Aculys Pharma, including exclusive rights to pitolisant in Japan and Spydia® in Japan and certain Asia-Pacific markets.
• Biocon Biologics Transaction completed in December 2025 with total consideration of $815 million: $400 million cash and $415 million in newly issued Biocon equity shares subject to a six-month lock-up period.December 2025
• Divestiture of API and women’s healthcare businesses.
• Over-the-Counter (OTC) Transaction.
• China implemented a Quality Consistency Evaluation (QCE) process for post-LOE products starting in 2013, requiring bioequivalence tests to a qualified reference drug.2013
• Effective January 1, 2024, China implemented measures stipulating additional responsibilities for marketing authorization holders and medical institutions for drug quality management.January 1, 2024
• Since 2018, China's National Healthcare Security Administration has been promoting a centralized Volume-Based Procurement (VBP) policy, resulting in price cuts up to 96%.2018
• In 2022, the Inflation Reduction Act introduced Medicare drug price negotiation for certain high-spend, single-source drugs, inflation-based rebates for certain Medicare drugs, and a redesign of Medicare Part D.2022
• Changes to or reductions in subsidies of individual insurance plans on the healthcare exchanges in 2026 have led to a reduction in the number of individuals with health insurance in the U.S.2026
• Goodwill impairment charge of $2.94 billion recorded in 2025.2025
• Loss of market exclusivity for Amitiza® 24 μg in Japan expected in June 2026.June 2026
• December 2024 FDA warning letter and import alert related to the oral finished dose manufacturing facility in Indore, India, restricting distribution of certain products into the U.S. and negatively impacting sales.December 2024
• Temporary suspension of manufacturing at the Nashik, India facility due to a fire in February 2026.February 2026
• Manufacturing and supply agreement entered into with the purchaser of the API business, increasing dependency on that purchaser for a significant amount of API.
• In 2026, Viatris is anticipating regulatory responses on several products, including its low dose estrogen weekly patch for contraception and fast-absorbing formulation of meloxicam.2026
• On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act with permanent extensions of most expiring Tax Cuts and Jobs Act provisions and international tax changes.July 4, 2025
• Board of Directors authorized a $2 billion share repurchase program, with $1.0 billion remaining available as of February 26, 2026.February 26, 2026
• The U.S. Inflation Reduction Act of 2022 imposed a corporate excise tax of 1% on net stock repurchases and a 15% corporate alternative minimum tax on adjusted financial statement income.2022